名称未設定-1
|
|
|
- ひろと やたけ
- 9 years ago
- Views:
Transcription
1 2013 Expanding Leading-edge Innovations
2 ,4770.8% % %
3 1
4 > > > % 2
5 > > > 50.0% % > > BBI > 3 3
6 LD/HD24 ARB HD 10mg BBI BBI CEO R&D EMA P.8
7 0.8%3, % %100 4,000 3,000 3,795 3,504 3,477 2,963 2,640 1,600 1, ,302 1, , ,000 1, ,000 8,000 4, , , , , , , ,488 7, ,296 4, EBITDAEarnings Before Interest, Taxes, Depreciation and Amortization 2ROE 3ROA 5
8 Expanding Leading-edge dge Innovations dg
9 Contents BBI608BBI CSR ISO ISO
10 : 8
11 9 Q.1 BBI 2
12 Q MR MR MR MR2013 Q.3 BBI608BBI503 BBI WT WT1 BBI608BBI503 10
13 Q.4 BBI CNS CNS MRe- 11
14 Q.5 POCProof of Concept BBI BBICEOR&D PC iPS Global Oncology LGLead GenerationLOLead Optimization 12
15 Q Q.7 CSR21 2QOL 2 Q.8 13
16 BBI
17 20134 LG 1 LO 2 1 LGLead Generation 2 LOLead Optimization BBI BBICEO CSOChief Scientific OfficerR&D GBSCGlobal Business Strategy Committee GRDC Global R&D Committee GCD Global Clinical Development Head of GCD Head of GCD Global Oncology 15
18 POC POC SB623 BBI BBI608BBI503 WT2725 POCProof of Concept POC NDDC DSKiPS ips ips
19 inips BBI COPDSUN ips ips EPI-743EPI-589 CEO mg FDA 17
20 20129 EMA DSP-2230 Nav1.7Nav ADHDSEP SEP TBial FDA 11 / SB623 / BBI2 BBI608BBI503 BBI BBI / Top Ten Promising Late Stage Cancer Drugs Fierce Biotech BBI WT4869WT2725 WT1 18
21 WT1T CTLWT1 CTL WT4869 MDS/ DSP-3025 Toll-like receptor 7TLR7 AstraZeneca AstraZeneca4 WT COPDSUN-101 DSP-3025 SUN g20131 IBSDSP- 6952Intercept NASHDSP-1747 DSP-1747 PBC DSP-1747 InterceptINT-747 FXR Farnesoid Xreceptor NASH Intercept PBCNASH / NASH SUN-101glycopyrrolate eflow SUN-101 LAMA COPD 19
22 20
23 21
24 22 4 GMP FDA EMATGA GMP ICH EU RABS 4 GMP
25 マーケティング 国内医薬品市場では 成長品目へのリソース集中による売上の拡大 北米市場では ラツーダ の製品価値最大化に 注力しています 基本方針 北米事業では ラツーダ の利益最大化を最優先しつ 当社では 第三期中期経営計画の基本方針として 強 つ サノビオン ファーマシューティカルズ インク 以下 サ 固な国内収益基盤の確立 海外事業の収益最大化とさ ノビオン社 の既存製品販売体制の最適化をはじめとし らなる事業拡大 などを掲げています た経営効率のさらなる向上を推進しています 国内医薬品事業では 成長品目での売上拡大に向け 中国事業では メペム メロペン をはじめとした既 戦略品である アイミクス アバプロ ロナセン トレ 存製品の販売拡大および新製品の投入により 事業規模 リーフ や 新製品である メトグルコ シュアポスト パ と収益の最大化を図っています キシルCR などへ 営業資源を集中しています エリア別マーケティング体制 2013 年 3 月 31 日現在 中国 MR 数 米国 MR 数 3,072億円 経営効率化のさらなる推進 日本 MR 数 1,410 名 医薬品事業 売上高目標 地域別 3,101億円 ラツーダ の利益最大化 350 名 既存製品の利益拡大 新製品の投入 830 名 成長品目へのリソース集中 3,256 億円 海外その他 中国 北米 日本 年度 予想 MR 医薬情報担当者 アニュアルレポート
26 1,745 MR 1, ,000 1,500 1, ,799 1,745 1, CNS
27 25 MR e CR CR SSRI % % ACE ARB 24 ARB AVAPRO APROVEL
28 ARB % % CR SSRI SU 2 A1c
29 %112.3% 468.7% %142 B B Gene Activation technology CTH
30 1,158 MR % 134.5% ,500 1, ,084 1,158 1, CM 20141Q % %6.4% MR MR 28
31 20128 Inhalation Solution COPD % 25.3% SUN-101COPD MR HFA COPD 29
32 MR MR % E / 30
33 DSP DS DS POCTPoint of Care TestingCa ESiPS Companion Diagnostics SS POCT 31
34 CSR CSR CSR ISO26000 ISO CSR 32
35 ISO26000 ISO26000 P P.34, 35, 4 P P P.40 3 P.35, 40. P.34, 35, P.39 P.34, 39 P.41 33
36 Good Clinical Practice:GCP 2012DVD 34
37 % OJTOn-the-Job Training OffJTOff-the-Job Training OJTOffJT 38% 19% 19% 9% 9% 6%
38 OUTPUT OUTPUT O INPUT
39 PRTR % CO CO CO % 108% CO2 CO % % 1% % %
40 CO2 CO CO % CO2 CO2 3R ,314t 21% 7,628t 21% 14.9t18% 0.1%1% 1% % CO ,000 10,000 8,000 6,000 4,000 2,
41 TDnet ISO
42 ,000 DI-SaGaS FAQ QA MR MR MR MR Shink MR ShinkShink SafetyThink MR e- MR MR MR Shink , % 19.6% 19.0% 11.1% 8.3% 8.6% 2.7% 40
43 20125 NPO MNMJ TABLE FOR TWO TABLE FOR TWO 120 TABLE FOR TWO International 1 41
44 SUKOYAKA SUKOYAKA ,800 42
45 50.22%
46 GCC 44
47 2012 BCP IT Act Plan Do Check 45
48 IR
49 URL:
50 DSP& Vice Chair, Executive Vice President and Chief Financial Officer Executive Vice President Head of Global Clinical Development for DSP Group IT Executive Vice President and Chief Medical Officer Antony Loebel BBI President, Chief Executive Officer and Chief Medical Officer Head of Global Oncology for DSP Group Chiang J. Li 48
51 Contents
52 , , , , , , , ,226 53,015 22, % 37.2% 40.1% 17.9% 8.4% 101,686 98, , , , , , , , ,130 25,044 20,402 30,952 35,625 31,166 18,158 16,328 25,050 31,423 32,168 10,044 8,630 16,796 20,958 19,988 37,174 2,396 (12,066) 27, , , , , ,540 69,862 66,697 69,794 74,084 69, , , , , , , , , ,000 53, , , ,681 18,260 13, , , , , ,496 59,844 56,891 68,160 51,371 52,819 12,384 8,742 8,663 6,471 10,569 35,085 40,232 44,628 18,650 11,455 60,333 59,880 77,971 56,448 41, % 5.8% 8.2% 12.0% 11.8% 3.0% 2.7% 5.0% 6.3% 6.2% 1.7% 1.5% 2.8% 4.1% 5.1% 57.5% 57.1% 54.9% 54.8% 82.9% 50
53 263, , , , , ,554 (0.8%) $3,699,191 24,521 22,032 9,696 3,820 3,630 3, % 1,416, % 8.4% 3.9% 2.2% 2.1% 2.3% 99,385 99, , , , , % 1,081, , ,312 86,461 52,404 51,546 51,240 (4.4%) 2,351,000 39,814 45,555 28,886 11,585 10,113 13, % 266,426 41,457 38,415 25,687 11,686 13,836 12, % 193,170 25,592 22,605 15,377 6,924 7,968 6, % 106,851 1,451.5% 395, , , , , , ,241 (0.2%) 3,547,223 70,280 65,241 68,336 32,611 34,473 35, % 743, , , , , , , % 6,459,777 67,915 56,039 80,071 49,196 45,927 60, % 1,327,990 13,598 20,484 24,262 16,802 16,258 9,248 (0.8%) 1,416, , , , , , , % 3,715,404 47,266 40,870 29,636 17,444 15,929 15, % 636,638 15,491 9,543 6,616 3,064 4,294 6, % 131,745 11,870 12,008 8,901 5,233 5,821 5,316 (12.8%) 373,245 48,802 54,875 36,179 16,446 16,040 18, % 641, % $ % % % 17.4% 11.8% 6.6% 5.9% 7.7% 8.2% 7.6% 7.3% 5.2% 6.5% 5.5% 6.5% 5.8% 5.2% 3.5% 4.2% 3.4% 79.6% 79.8% 73.2% 66.8% 67.1% 61.9% 51
54 BBI 9 9 SRD % %3, , ,460 2,000 1, ,000 3,000 2,640 2, , , ,
55 , % 1, % 50% 33% 2 3% 12%
56 1, % %1, % % % % % % % % %
57 ,500 5,000 6,267 5,899 6,072 5,594 3, ,072 BBISRD 83,334 BBISRD 455 2,039 BBI 1782, , % 2, , ,000 2,000 1, , ,435 3,492 3,240 3,
58 BBISRD ,500 1, ,000-1,500-2, (213) (118) 1,319 (1,518) (66) (44) (203) (202) (329) (550) % 82.9% 54.8% 54.9% 57.1% 57.5% 90.6% 83.1% 54.3% 52.2% 62.3% 114.8% 17.5% 8.5% 431.2% 218.4% 205.4% 195.9%
59 EBITDA ,690 3, % % % ,
60 58
61 59
62 ,753 12,953 $ 199,500 86,463 99, ,819 2,897 2,971 30,819 95,093 99,653 1,011,628 34,574 25, ,808 (105) (110) (1,117) 132, ,564 1,409,138 62,689 58, ,904 30,098 31, ,191 2,977 4,715 31, , ,251 3,547,223 10,277 10, ,330 92,586 91, , , ,959 1,120,777 5,799 2,121 61, , ,444 2,276,755 (144,153) (141,747) (1,533,542) 69,862 66, , ,426 40,059 29, ,160 71,294 64, ,447 50,664 5, ,979 24,352 37, ,064 7,570 11,625 80,532 8,999 9,075 95, , ,462 2,169, , ,410 $ 6,459,777 60
63 20,000 10,000 $ 212, ,518 2,118 46,812 2,115 44,404 11, , ,488 2,280 44,919 5,437 40,163 5, ,966 1, ,596 22, ,000 22, , ,340 1,327,989 95,000 11,030 27, , ,000 10,790 5, ,217 1,010, , ,406 1,416,384 22,400 22, ,298 15, ,557 (651) 15, ,664 (649) 168,723 3,282,522 (6,926) 346, ,275 3,682,617 14,121 (11,039) 3, , ,219 8,016 (32,064) (24,048) 319, , ,223 (117,436) 32,787 3,715,404 $6,459,777 61
64 , , , ,994 25,044 1,091 (1,072) (417) (4,841) (1,090) (557) (6,886) 18,158 6,788 1,326 8,114 10, ,044 6,105 21,025 27,130 37,174 37, ,396 98, , ,137 20,402 1,025 (1,123) (2,338) (224) 1,241 (1,224) (1,431) (4,074) 16,328 12,291 (4,593) 7,698 8, ,630 2,602 (8,836) (6,234) 2,396 2,396 $3,699,191 1,081,765 2,617,426 2,351, ,426 11,606 (11,404) (4,436) (51,500) (11,596) (5,926) (73,256) 193,170 72,213 14,106 86,319 $ 106,851 $ $ 106,851 64, , , , ,468 62
65 ,900 (587) 22,400 15, ,186 (649) 341,797 5,414 (23,228) (17,814) 323,983 (7,152) (7,152) (7,152) 8,630 8,630 8,630 (2) (0) (0) (0) 0 (0) ,602 (8,836) (6,234) (6,234) 397,900 (589) 22,400 15, ,664 (649) 343,275 8,016 (32,064) (24,048) 319,227 (7,151) (7,151) (7,151) 10,044 10,044 10,044 (1) (2) (2) (2) (0) 6,105 21,025 27,130 27, ,900 (590) 22,400 15, ,557 (651) 346,166 14,121 (11,039) 3, ,248 $238,298 $168,723 $3,251,745 $(6,904) $3,651,862 $ 85,276 $(341,106) $(255,830) $3,396,032 (76,074) (76,074) (76,074) 106, , ,851 (22) (22) (22) (0) , , , ,617 $238,298 $168,723 $3,282,522 $(6,926) $3,682,617 $150,223 $(117,436) $ 32,787 $3,715,404 63
66 ,158 31, ,773 (228) (1,091) 1,072 4,841 6,806 (3,732) (4,877) 6,837 63,288 1,442 (1,074) (3,627) (10,115) 49,914 (5,179) (7,818) (2,209) 18 (4,926) 3 (2,344) 265 (24,852) (7,981) 3 (55,020) (13,000) (2) (7,151) (68) (20,221) 4,582 (20,745) 92,179 71,434 16,328 36,468 2,338 3,764 (130) (1,025) 1, ,224 5,824 (2,585) (2,490) 1,570 62,633 1,349 (1,106) (14,493) 48,383 (6,715) (2,136) 1,945 5, (3,203) 47 (22) (4,373) (50,000) 19,895 15,000 (10,600) (1) (7,149) (68) (32,923) (1,776) 9,311 82,868 92,179 $ 193, ,106 4,436 40,138 (2,426) (11,606) 11,404 51,500 72,404 (39,702) (51,883) 72, ,277 15,340 (11,426) (38,585) (107,606) 531,000 (55,096) (83,170) (23,500) 191 (52,404) 32 (24,936) 2,819 (264,383) (84,904) 32 (585,319) (138,298) (21) (76,074) (725) (215,118) 48,745 (220,692) 980,628 $ 759,936 64
67 TEL FAX TEL FAX ,1294, ,900, , SMBC UFJ DSP& DS DS 199, , , , , , , , , BNY GCM CLIENT ACCOUNT JPRD AC ISG FE-AC 3, % 10.05% 1.71% 19.33% 0.15% 60.01% 2, , ,000 1,500 80,000 1,000 60,000 40, ,
68 TEL FAX TEL FAX
.......p...{..P01-48(TF)
1 2 3 5 6 7 8 9 10 Act Plan Check Act Do Plan Check Do 11 12 13 14 INPUT OUTPUT 16 17 18 19 20 21 22 23 24 25 26 27 30 33 32 33 34 35 36 37 36 37 38 33 40 41 42 43 44 45 46 47 48 49 50 51 1. 2. 3.
技術流出防止指針公表用.PDF
15 3 1 4 .. 2 2.. 4. 6.10 10.14.16.19.24.26.28 1 2 1 2002 7 3 2002 3 4 2 3 5 4 4 6 7 8 5 5 9 plan (do) (check) (act) 1) 2) 3) 4) 5) 6) 7) 10 11 12 13 14 15 16 17 18 6 6 19 / / 20 21 22 7 23 8 24 25 26
,889 99, , , ,031 8,952 13,261 16,443 14,464 17,948 % ,037 8,848 10,927
2013 2013 3 3 313 31 2008 2009 2010 2011 2012 90,889 99,764 104,069 103,232 107,031 8,952 13,261 16,443 14,464 17,948 % 9.8 13.3 15.8 14.0 16.8 2,037 8,848 10,927 9,231 12,422 % 2.2 8.9 10.5 8.9 11.6 4,575
KAITEKIレポート
INDEX R e p o r t Corporate Social Responsibility 1 2 2011 3 11 MCHC 616 26 6 MCHCGood Chemistry for Tomorrow APTSIS 10 20253 Sustainability Health Comfort 3 MBA Master of Business Administration MOT Management
col_ARJ_CV0303入稿.indd
COLOPL 2015 2014.10.1 2015.9.30 About COLOPL Entertainment in Real Life VR VR PC VR 2003 Internet Personal Computer 1 8 Unity 2 3 Web 2013 VR 2016 VR 2011 2008 Virtual Reality VR Smartphone Feature Phone
LIFULL アニュアルレポート 2017
LIFULL LIFULL ANNUAL REPORT 2017 Contents 2 4 6 12 16 Vision and Strategy 18 LIFULL 20 LIFULL Value Model 22 22 24 26 28 28 30 30 34 CFO&CSO Fact Data 38 40 3 41 42 44 45 2017 4 1 LIFULL ANNUAL REPORT
untitled
215 214 12 ENERGIZING THE FUTURE IIRC ver 1. CONTENTS 2 OUR ROAD 8 12 12 CEO 18 CFO 2 2 22 3 32 38 4 4 46 49 54 56 63 CSR Book WEB CSR http://www.showa-shell.co.jp/ csr/index.html 215 1 OUR ROAD 3 3 1985
Quality of Life Human Chemistry, Human Solutions Quality of Life Quality of Life HumanChemistry HumanSolutions ChemistrySol
2006 CSR 2005 7519936Quality of Life 1020034 Human Chemistry, Human Solutions Quality of Life 1 2 3 Quality of Life 1 2 3 HumanChemistry HumanSolutions ChemistrySolutions21 Chemistry 1 TEIJIN CSR Report
untitled
Report 214 21412 FEATURE-1 1 HORIBA FPD HORIBA Report 214 2 FEATURE-1 HORIBACSR HORIBA HORIBA 1945 195 1955 196 1965 197 1975 1945 1953 197 1974 1971 195 ph 1964 M EXA 19771978 3 1,53 172 198 1985 199
ニコンレポート2016
NIKON REPORT 216 216 216 3 1 2171 19171 216 3Next 1 - Transform to Grow 6 216 2171215 1 http://www.nikon.co.jp/profile/museum/ ABOUT NIKON 2 4 6 BUSINESS STRATEGY 8 9 14 16 BUSINESS PERFORMANCE 18 22 216
Contents LINK TO GOOD LIVING 1
5938 216 3 215 4 1216 3 31 Contents... 2... 3... 7... 9... 11... 13... 14... 18... 19... 21... 22... LINK TO GOOD LIVING 1 LIXILCEO 5 3 IoT 6 3 INAX LIXIL CEO 2 196 6 1983 2 MonotaRO MonotaRO11 21 MonotaRO
2 1,384,000 2,000,000 1,296,211 1,793,925 38,000 54,500 27,804 43,187 41,000 60,000 31,776 49,017 8,781 18,663 25,000 35,300 3 4 5 6 1,296,211 1,793,925 27,804 43,187 1,275,648 1,753,306 29,387 43,025
平成20年度内部評価実施結果報告書《本編》
10 11 12 13 14 15 16 17 Plan Do Check Action 1 2 3 4 146 13 20 43 44 45 62 104 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47
-2-
-1- -2- -3- -4- -5- -6- -7- -8- 10-9- -10-1 2 -11-1 1-12- -13- -14- Plan Do Check Action Check Action 1 -15- -16- -17- -18- -19- -20- -21- -22- 10 2 9 3 9 2 1 10 2 9 3 6 4 1 6 6 10 2 10 2 11 1 8 1 8 4
SMBC Group Report 2018 CEO CEO SMBC Group Report 2018 1 SMBC 4 SMBC 6 7 ESG 10 SMBC 12 CEO 20 22 CFO 27 28 30 32 34 36 38 40 42 SMBC SMBC Group Report 2018 IIRC 2013 12 SMBC Group Report 2018 CSR 2017
CONTENTS
Annual Report 2017 CONTENTS Santen Pharmaceutical Co., Ltd. Annual Report 2017 1 Value Creation 2 Santen Pharmaceutical Co., Ltd. Annual Report 2017 Santen Pharmaceutical Co., Ltd. Annual Report 2017 3
三越伊勢丹ホールディングスレポート 2018 CSR
三越伊勢丹ホールディングスレポート 2018 CSR Contents 02 03 07 13 23 27 31 39 43 51 53 CSR 2019 3 31 01 ISETAN MITSUKOSHI HOLDINGS 私たちの考え方 INTEGRATED REPORT 2018 02 三越伊勢丹グループについて 数字で見る三越伊勢丹グループ 2 6 63 1 18 4 2 4 24100 34
MSD Human Resources Global Compliance Organization Office of Ethics Global Safety and the EnvironmentGlobal Compliance Organization Office of Ethics O
Be well III MSD Human Resources Global Compliance Organization Office of Ethics Global Safety and the EnvironmentGlobal Compliance Organization Office of Ethics Office of Ethics Office of Ethics OFFICE
avex-Pages.indd
Backstage Value Multiplier 21 9.4.1-1.3.31 Giving Life to a Blossoming Crescendo avex group 1 : 25 26 27 28 29 1 ORANGE RANGE EXILE 2 EXILE 3 Mr. Children B'z 4 SMAP EXILE B'z 5 KAT-TUN 6 EXILE KAT-TUN
5 10 10-1 - 5 20-2 - - 3 - - 4 - 22 6 30 10 12 22 7 8 1 30 4 30 1 22 7 14 10 12 20 22 7 21 1 30 3 30-5 - - 6 - - 7 - 11 9 9 14 10 9 15 7 9 10 NPO - 8 - - 15 - - 16 - - 17 - - 19 - - 20 - - 21 - - 22
90 27 1 29 ( ) 27 4 26 ( ) 27 4 29 ( ) 4 27 3 30 ( ) 1 30 4 27 4 8 ( ) 16 ( ) 9 P2 3 301 27 4 14 ( ) 15 ( ) 9 5 27 4 21 ( ) 4 27 4 21 ( ) 8 30 5 27 4 23 ( ) 5 10 11 12 13 4 3 4 14 27 4 23 ( 27 4 25 ( )
Lixil_H1-4_13_PDF.indd
2012 Our Business, Our CSR C O N T E N T S 08 Feature 1 04 Feature 2 14 02 06 Feature 3 20 g 24 Report 1 Report 4 29 33 Report 7 26 Report 2 30 Report 5 Report 8 34 Report 3 28 Report 6 32 35 03 04 Management
CEO ,19 6, , ,597 12,229 16,389 18, ,48 CIS 3,326 1,65 3, ,358 2, 17,19 15, 14,3
Environmental & Social Report 26 19211513 17-8414 36 CEO 678 2631 25 17,19 6,273 157 263 5,979 263 34,597 12,229 16,389 18,28 263 7,48 CIS 3,326 1,65 3,214 791 1,358 2, 17,19 15, 14,347 1,963 1,898 11,964
ニコンレポート2017
NIKON REPORT 217 217 217 3 Unlock the future with the power of light 217 7 251 1 1 1 217216 11 Unlock the future with the power of light 2 NIKON REPORT 217 BUSINESS STRATEGY 2 3 8 CFO 1 1 12 FAQ 13 TOPICS
thermometer AnnuAl RepoRt 2011 Terumo CorporaTion
2011 2011 3 1921 10 thermometer 1921 1853 1931 AnnuAl RepoRt 2011 Terumo CorporaTion 2011 5 01 Introduction MRS. GIeSeKe 1994 DuraHeart DuraHeartDuraHeart 5 DuraHeart DuraHeart DuraHeart duraheart 2007
untitled
CONTENTS 1 2 4 6 8 10 11 12 14 15 16 17 18 19 20 21 22 23 24 27 28 29 30 31 32 33 Top Message 2 Daifuku Co., Ltd. CSR Report 2010 Daifuku Co., Ltd. CSR Report 2010 3 4 Daifuku Co., Ltd. CSR Report 2010
untitled
27.4.1 s 28.3.31 31 8515 Vol.24 June 28 Top Message 283 1 16 4 17 5 Topics 18 CSR 7 19 1 2 12 21 21 4,574,99 321,63274 1 3 Top Message 2 4,112 33 317 2825 7 64%5% ROA1.5% 5, 1, 15, 2, 25, 3, 25,225 25/3
maiji2007_cover_j_0907
27 CORPORATE PHILOSOPHY THE MEIJI DAIRIES GROUP CONTRIBUTES TO A HEALTHY AND HAPPY DAILY LIFE FOR OUR CUSTOMERS BY OFFERING NEW LEVELS OF VALUE IN FOOD. CONTENTS 2 4 6 1 1 11 12 13 14 16 18 19 2 22 23